What topics does this cannabis study cover?

This study covers research on: Cancer.

Where was this research published?

Published in Drug delivery and translational research on February 11, 2026.

Cannabinoids show promise against drug-resistant breast cancer

Pharmacokinetic studies and synergistic antitumor effects of cannabichromene and cannabidiol in drug-resistant breast cancers.

Drug delivery and translational research • February 11, 2026 • Moderately Relevant

🤖

AI Summary

In a groundbreaking study, researchers explored the potential of two lesser-known cannabinoids, cannabichromene (CBC) and cannabidiol (CBD), in combating a challenging type of breast cancer. Triple-negative breast cancer (TNBC) is particularly aggressive and resistant to traditional treatments, making it difficult to manage. The study focused on drug-resistant TNBC cells, demonstrating how these cannabinoids could offer a promising new approach to cancer treatment.

The research revealed remarkable synergistic effects when CBC and CBD were combined. In laboratory and animal studies, the cannabinoid duo showed impressive anti-cancer capabilities, including reducing tumor volume by up to four times compared to control groups. The combination worked by targeting multiple cancer-promoting pathways, downregulating key proteins that drive cancer cell growth and spread. Notably, the cannabinoids reduced cancer cell invasiveness by approximately 55% and induced cell cycle arrest, potentially slowing cancer progression.

Importantly, the study also examined the pharmacokinetics of these cannabinoids, finding that co-administration enhanced their systemic absorption. This means the combination could potentially be more effective and bioavailable than individual treatments. While more research is needed, this study represents a significant step forward in exploring cannabinoids as a potential treatment for drug-resistant breast cancer, offering hope for patients with limited therapeutic options.

📄 Original Abstract

Triple-negative breast cancer (TNBC) is highly aggressive with limited treatment options, and resistance to doxorubicin (DOX) further compromises outcomes. Cannabinoids such as cannabichromene (CBC) and cannabidiol (CBD) possess anticancer properties, but their combined effects in resistant TNBC remain unexplored. This study evaluated the antitumor efficacy of a CBC + CBD combination against DOX-resistant (DOX-RT) TNBC using in vitro, in vivo, and pharmacokinetic models. Cytotoxicity was assessed in DOX-RT MDA-MB-231 cells using 2D and 3D assays, with synergy confirmed by combination index (CI) analysis. Cell cycle and invasion assays were performed. Xenograft studies were conducted in BALB/c nude mice bearing DOX-RT tumors treated intraperitoneally with CBC (10 mg/kg), CBD (20 mg/kg), or CBC + CBD. Pharmacokinetics were evaluated in rats, complemented by GastroPlus™ simulations. CBC + CBD synergistically inhibited cell growth induced G0/G1 arrest, and reduced invasiveness by ~ 55% in a Transwell Matrigel invasion assay. In xenografts, combination therapy reduced tumor volume by two-folds compared to single treatments and fourfolds versus control. Western blotting revealed downregulation of MEK/ERK, PI3K/AKT/mTOR, Cyclin D1, CDK6, SOD2, and NF-κB. Pharmacokinetic studies showed co-administration increased Cmax and AUC without altering Tmax, supported by simulations predicting enhanced jejunal absorption. CBC + CBD co-therapy demonstrates synergistic efficacy against resistant TNBC by inhibiting oncogenic pathways and enhancing systemic exposure. This first study of its kind highlights CBC + CBD as a promising strategy to overcome DOX resistance in TNBC.

Paper Type

📄 Research

Publication

Journal: Drug delivery and translational research
Published: February 11, 2026
PMID: 41670942
DOI: 10.1007/s13346-026-02057-1

Authors (7)

Mounika Aare College of Pharmacy and Pharmaceutical Sciences, Florida A&M University, Tallahassee, FL, 32307, USA.
Sandeep Chary Padakanti College of Pharmacy and Pharmaceutical Sciences, Florida A&M University, Tallahassee, FL, 32307, USA.
Arvind Bagde College of Pharmacy and Pharmaceutical Sciences, Florida A&M University, Tallahassee, FL, 32307, USA.
Jassy Mary Lazarte College of Pharmacy and Pharmaceutical Sciences, Florida A&M University, Tallahassee, FL, 32307, USA.
Satyanarayan Dev College of Agriculture and Food Sciences, Florida A&M University, Tallahassee, FL, 32307, USA.
+2 more authors